The DOI matches its Crossref record; 64 of the 64 references it cites were found in a registry or an index.
Meeting Highlights: Updated International Expert Consensus on the Primary Therapy of Early Breast Cancer
Abstract
This account of the highlights of the eighth St Gallen (Switzerland) meeting in 2003 emphasizes new information that has emerged during the 2 years since the seventh meeting in 2001. This article should be read in conjunction with the report of that earlier meeting. Recommendations for patient care are so critically dependent on assessment of endocrine responsiveness that the importance of high-quality steroid hormone receptor determination and standardized quantitative reporting cannot be overemphasized. The International Consensus Panel modified the risk categories so that only endocrine receptor–absent status was sufficient to reclassify an otherwise low-risk, node-negative disease into the category of average risk. Absence of steroid hormone receptors also was recognized as indicating endocrine nonresponsiveness. Some important areas highlighted at the recent meeting include: (1) recognition of the separate nature of endocrine-nonresponsive breast cancer—both invasive cancers and ductal carcinoma-in-situ; (2) improved understanding of the mechanisms of acquired endocrine resistance, which offer exciting prospects for extending the impact of successful sequential endocrine therapies; (3) presentation of high-quality evidence indicating that chemotherapy and tamoxifen should be used sequentially rather than concurrently; (4) availability of a potential alternative to tamoxifen for treatment of postmenopausal women with endocrine-responsive disease; and (5) the promise of newly defined prognostic and predictive markers.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Molecular portraits of human breast tumours
Perou, C. M., Sørlie, T., Eisen, M. B., van de Rijn, M., Jeffrey, S. S., Rees, C. A., Pollack, J. R., Ross, D. T., Johnsen, H., Akslen, L. A., et al. (2000) · Nature · doi:10.1038/35021093 · Cited by 16,261
A Gene-Expression Signature as a Predictor of Survival in Breast Cancer
van de Vijver, M. J., He, Y. D., van 't Veer, L. J., Dai, H., Hart, A. A. M., Voskuil, D. W., Schreiber, G. J., Peterse, J. L., Roberts, C., Marton, M. J., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021967 · Cited by 6,488
Fisher, B., Costantino, J. P., Wickerham, D. L., Redmond, C. K., Kavanah, M., Cronin, W. M., Vogel, V., Robidoux, A., Dimitrov, N., Atkins, J., et al. (1998) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/90.18.1371 · Cited by 5,485
Veronesi, U., Cascinelli, N., Mariani, L., Greco, M., Saccozzi, R., Luini, A., Aguilar, M., & Marubini, E. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020989 · Cited by 4,450
Tamoxifen for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(97)11423-4 · Cited by 4,085
Focan, C., Steinberg, S. M., Blichert-Toft, M., Forbes, J., Collins, R. D., Anderson, S., Margreiter, R., Harwood, C. S., Andersen, K., Beighton, G., et al. (1998) · PubMed · Cited by 2,146
Self-citationHarvey, J. M., Clark, G. M., Osborne, C. K., & Allred, D. C. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.5.1474 · Cited by 2,056
Polychemotherapy for early breast cancer: an overview of the randomised trials
(1998) · The Lancet · doi:10.1016/s0140-6736(98)03301-7 · Cited by 2,042
Citron, M. L., Berry, D. A., Cirrincione, C., Hudis, C., Winer, E. P., Gradishar, W. J., Davidson, N. E., Martino, S., Livingston, R., Ingle, J. N., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.09.081 · Cited by 1,564
Prophylactic Oophorectomy in Carriers of BRCA1 or BRCA2 Mutations
Rebbeck, T. R., Lynch, H. T., Neuhausen, S. L., Narod, S. A., van't Veer, L., Garber, J. E., Evans, G., Isaacs, C., Daly, M. B., Matloff, E., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa012158 · Cited by 1,465
Fisher, B., Jeong, J.-H., Anderson, S., Bryant, J., Fisher, E. R., & Wolmark, N. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa020128 · Cited by 1,400
Henderson, I. C., Berry, D. A., Demetri, G. D., Cirrincione, C. T., Goldstein, L. J., Martino, S., Ingle, J. N., Cooper, M. R., Hayes, D. F., Tkaczuk, K. H., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.02.063 · Cited by 1,294
Self-citationRevision of the American Joint Committee on Cancer Staging System for Breast Cancer
Singletary, S. E., Allred, C., Ashley, P., Bassett, L. W., Berry, D., Bland, K. I., Borgen, P. I., Clark, G., Edge, S. B., Hayes, D. F., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.02.026 · Cited by 1,173
Ellis, M. J., Coop, A., Singh, B., Mauriac, L., Llombert-Cussac, A., Jänicke, F., Miller, W. R., Evans, D. B., Dugan, M., Brady, C., et al. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3808 · Cited by 1,060
Winer, E. P., Hudis, C., Burstein, H. J., Wolff, A. C., Pritchard, K. I., Ingle, J. N., Chlebowski, R. T., Gelber, R., Edge, S. B., Gralow, J., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.09.121 · Cited by 1,031
Self-citationRavdin, P. M., Siminoff, L. A., Davis, G. J., Mercer, M. B., Hewlett, J., Gerson, N., & Parker, H. L. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.4.980 · Cited by 996
Overview of the main outcomes in breast-cancer prevention trials
Cuzick, J., Powles, T., Veronesi, U., Forbes, J., Edwards, R., Ashley, S., & Boyle, P. (2003) · The Lancet · doi:10.1016/s0140-6736(03)12342-2 · Cited by 965
Bartelink, H., Horiot, J.-C., Poortmans, P., Struikmans, H., Van den Bogaert, W., Barillot, I., Fourquet, A., Borger, J., Jager, J., Hoogenraad, W., et al. (2001) · New England Journal of Medicine · doi:10.1056/nejmoa010874 · Cited by 941
Braun, S., Pantel, K., Müller, P., Janni, W., Hepp, F., Kentenich, C. R. M., Gastroph, S., Wischnik, A., Dimpfl, T., Kindermann, G., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200002243420801 · Cited by 923
Osborne, C. K., Bardou, V., Hopp, T. A., Chamness, G. C., Hilsenbeck, S. G., Fuqua, S. A. W., Wong, J., Allred, D. C., Clark, G. M., & Schiff, R. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.353 · Cited by 786
(2002) · The Lancet · doi:10.1016/s0140-6736(02)09962-2 · Cited by 747
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Wood, W. C., Senn, H.-J., Glick, J. H., & Gelber, R. D. (1995) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/87.19.1441 · Cited by 689
Self-citationFisher, B., Brown, A. M., Dimitrov, N. V., Poisson, R., Redmond, C., Margolese, R. G., Bowman, D., Wolmark, N., Wickerham, D. L., & Kardinal, C. G. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.9.1483 · Cited by 620
Levine, M. N., Bramwell, V. H., Pritchard, K. I., Norris, B. D., Shepherd, L. E., Abu-Zahra, H., Findlay, B., Warr, D., Bowman, D., Myles, J., et al. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.8.2651 · Cited by 617
Look, M. P., van Putten, W. L. J., Duffy, M. J., Harbeck, N., Christensen, I. J., Thomssen, C., Kates, R., Spyratos, F., Ferno, M., Eppenberger-Castori, S., et al. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.2.116 · Cited by 596
Meeting Highlights: International Consensus Panel on the Treatment of Primary Breast Cancer
Goldhirsch, A., Glick, J. H., Gelber, R. D., Coates, A. S., & Senn, H.-J. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.18.3817 · Cited by 582
Self-citationOvarian ablation in early breast cancer: overview of the randomised trials
(1996) · The Lancet · doi:10.1016/s0140-6736(96)05023-4 · Cited by 561
Cyclin E and Survival in Patients with Breast Cancer
Keyomarsi, K., Tucker, S. L., Buchholz, T. A., Callister, M., Ding, Y., Hortobagyi, G. N., Bedrosian, I., Knickerbocker, C., Toyofuku, W., Lowe, M., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa021153 · Cited by 557
The Relation between Survival and Age at Diagnosis in Breast Cancer
Adami, H.-O., Malker, B., Holmberg, L., Persson, I., & Stone, B. (1986) · New England Journal of Medicine · doi:10.1056/nejm198608283150906 · Cited by 549
Younger women with breast carcinoma have a poorer prognosis than older women
Chung, M., Chang, H. R., Bland, K. I., & Wanebo, H. J. (1996) · Cancer · doi:10.1002/(sici)1097-0142(19960101)77:1<97::aid-cncr16>3.0.co;2-3 · Cited by 382
Very young women (<35 years) with operable breast cancer: features of disease at presentation
Colleoni, M., Rotmensz, N., Robertson, C., Orlando, L., Viale, G., Renne, G., Luini, A., Veronesi, P., Intra, M., Orecchia, R., et al. (2002) · Annals of Oncology · doi:10.1093/annonc/mdf039 · Cited by 371
Self-citationTamoxifen for Prevention of Breast Cancer
Cersosimo, R. J. (2003) · Annals of Pharmacotherapy · doi:10.1177/106002800303700219 · Cited by 343
Jonat, W., Kaufmann, M., Sauerbrei, W., Blamey, R., Cuzick, J., Namer, M., Fogelman, I., de Haes, J. C., de Matteis, A., Stewart, A., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.05.042 · Cited by 341
Bergh, J., Wiklund, T., Erikstein, B., Lidbrink, E., Lindman, H., Malmström, P., Kellokumpu-Lehtinen, P., Bengtsson, N.-O., Söderlund, G., Anker, G., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02841-5 · Cited by 339
Paik, S. (2000) · Journal of the National Cancer Institute · doi:10.1093/jnci/92.24.1991 · Cited by 304
Lindley, C., Vasa, S., Sawyer, W. T., & Winer, E. P. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.4.1380 · Cited by 296
Is chemotherapy alone adequate for young women with oestrogen-receptor-positive breast cancer?
Aebi, S., Gelber, S., Castiglione-Gertsch, M., Gelber, R., Collins, J., Thürlimann, B., Rudenstam, C., Lindtner, J., Crivellari, D., Cortes-Funes, H., et al. (2000) · The Lancet · doi:10.1016/s0140-6736(00)02292-3 · Cited by 287
Self-citationRadiotherapy-Related Lung Fibrosis Enhanced by Tamoxifen
Bentzen, S. M., Skoczylas, J. Z., Overgaard, M., & Overgaard, J. (1996) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/88.13.918 · Cited by 281
Survey of breast cancer patients concerning their knowledge and expectations of adjuvant therapy.
Ravdin, P. M., Siminoff, I. A., & Harvey, J. A. (1998) · Journal of Clinical Oncology · doi:10.1200/jco.1998.16.2.515 · Cited by 262
Informing and involving cancer patients in their own care
Jefford, M., & Tattersall, M. H. (2002) · The Lancet Oncology · doi:10.1016/s1470-2045(02)00877-x · Cited by 260
Ellis, P. M., Butow, P. N., Tattersall, M. H. N., Dunn, S. M., & Houssami, N. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.15.3554 · Cited by 244
Winer, E. P., Hudis, C., Burstein, H. J., Chlebowski, R. T., Ingle, J. N., Edge, S. B., Mamounas, E. P., Gralow, J., Goldstein, L. J., Pritchard, K. I., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.06.020 · Cited by 200
Colleoni, M., Bonetti, M., Coates, A. S., Castiglione-Gertsch, M., Gelber, R. D., Price, K., Rudenstam, C.-M., Lindtner, J., Collins, J., Thürlimann, B., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.3.584 · Cited by 197
Self-citationHarbeck, N., Kates, R. E., Look, M. P., Gelder, M. E. M., Klijn, J. G. M., Krüger, A., Kiechle, M. B., Jänicke, F., Schmitt, M., & Foekens, J. A. (2002) · PubMed · Cited by 191
Lessons learned from BRCA1 and BRCA2
Zheng, L., Li, S., Boyer, T. G., & Lee, W.-H. (2000) · Oncogene · doi:10.1038/sj.onc.1203968 · Cited by 188
Molenaar, S., Sprangers, M. A., Rutgers, E. J. T., Luiten, E. J., Mulder, J., Bossuyt, P. M., van Everdingen, J. J., Oosterveld, P., & de Haes, H. C. (2001) · Journal of Clinical Oncology · doi:10.1200/jco.2001.19.6.1676 · Cited by 174
Patient Preferences for Adjuvant Chemotherapy of Early Breast Cancer: How Much Benefit Is Needed?
Simes, R. J., & Coates, A. S. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003453 · Cited by 153
Self-citationVeronesi, U., Maisonneuve, P., Rotmensz, N., Costa, A., Sacchini, V., Travaglini, R., D’Aiuto, G., Lovison, F., Gucciardo, G., Muraca, M. G., et al. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.2.160 · Cited by 152
Love, R. R., Duc, N. B., Allred, D. C., Binh, N. C., Định, N. V., Kha, N. N., Thuân, T. V., Mohsin, S. K., Roanh, L. D., Khang, H. X., et al. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.2002.08.169 · Cited by 128
International Breast Cancer Study Group (1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.4.1385 · Cited by 113
Fumoleau, P., Kerbrat, P., Romestaing, P., Fargeot, P., Bremond, A. G., Namer, M., Schraub, S., Goudier, M.-J., Mihura, J., Monnier, A., et al. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.04.148 · Cited by 105
Colleoni, M. A., Minchella, I., Mazzarol, G., Nolè, F., Peruzzotti, G., Rocca, A., Viale, G., Orlando, L., Ferretti, G., Curigliano, G., et al. (2000) · Annals of Oncology · doi:10.1023/a:1008334404825 · Cited by 104
Self-citationPico, C., Martín, M., Jara, C., Barnadas, A., Pelegrí, A., Balil, A., Camps, C., Frau, A., Rodríguez-Lescure, Á., López-Vega, J. M., et al. (2003) · Annals of Oncology · doi:10.1093/annonc/mdh016 · Cited by 83
Contant, C., Menke-Pluijmers, M., Seynaeve, C., Meijers-Heijboer, E. J., Klijn, J. G., Verhoog, L., Wai, R. T. J., Eggermont, A., & van Geel, A. V. (2002) · European Journal of Surgical Oncology · doi:10.1053/ejso.2002.1279 · Cited by 78
Brooks, S. C., Saunders, D. E., Singhakowinta, A., & Vaitkevicius, V. K. (1980) · Cancer · doi:10.1002/1097-0142(19801215)46:12+<2829::aid-cncr2820461419>3.0.co;2-m · Cited by 46
Ovarian Ablation as Adjuvant Therapy for Breast Cancer
Davidson, N. E. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003464 · Cited by 44
Breast Cancer in the Very Young Patient: A Multidisciplinary Case Presentation
Mintzer, D. M., Glassburn, J. R., Mason, B. A., & Sataloff, D. M. (2002) · The Oncologist · doi:10.1634/theoncologist.7-6-547 · Cited by 36
Is Tamoxifen the Rosetta Stone for Breast Cancer?
Jordan, V. C. (2003) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/95.5.338 · Cited by 27
Who Should Not Receive Chemotherapy? Data From American Databases and Trials
Morrow, M., & Krontiras, H. (2001) · JNCI Monographs · doi:10.1093/oxfordjournals.jncimonographs.a003446 · Cited by 19
Optimum anthracycline-based chemotherapy for early breast cancer
Adlard, J., & Dodwell, D. J. (2001) · The Lancet Oncology · doi:10.1016/s1470-2045(01)00452-1 · Cited by 16
Radiotherapy to the conserved breast, chest wall, and regional nodes: is there a standard?
Bartelink, H. G. M. M. (2003) · The Breast · doi:10.1016/s0960-9776(03)00155-3 · Cited by 14
Adjuvant Chemotherapy for Postmenopausal Lymph Node-Negative Breast Cancer: It Ain't Necessarily So
Wolff, A. C. (2002) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/94.14.1041 · Cited by 13
Cited by
Trastuzumab after Adjuvant Chemotherapy in HER2-Positive Breast Cancer
Piccart-Gebhart, M. J., Procter, M., Leyland-Jones, B., Goldhirsch, A., Untch, M., Smith, I., Gianni, L., Baselga, J., Bell, R., Jackisch, C., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa052306 · Cited by 5,084
Self-citationGene-expression profiles to predict distant metastasis of lymph-node-negative primary breast cancer
Wang, Y., Klijn, J. G., Zhang, Y., Sieuwerts, A. M., Look, M. P., Yang, F., Talantov, D., Timmermans, M., Meijer-van Gelder, M. E., Yu, J., et al. (2005) · The Lancet · doi:10.1016/s0140-6736(05)17947-1 · Cited by 2,846
Paik, S., Tang, G., Shak, S., Kim, C., Baker, J., Kim, W., Cronin, M., Baehner, F. L., Watson, D., Bryant, J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.7985 · Cited by 2,579
Coombes, R. C., Hall, E., Gibson, L. J., Paridaens, R., Jassem, J., Delozier, T., Jones, S. E., Alvarez, I., Bertelli, G., Ortmann, O., et al. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040331 · Cited by 1,759
Self-citationDissecting the metastatic cascade
Pantel, K., & Brakenhoff, R. H. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1370 · Cited by 1,281
Metadata
- Authors
- Goldhirsch, A., Wood, W. C., Gelber, R. D., Coates, A. S., Thürlimann, B., & Senn, H.-J.
- Venue
- Journal of Clinical Oncology
- Published
- 2003-09-01
- Volume
- 21
- Issue
- 17
- Pages
- 3357-3365
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W1970797634
- Cited by
- 697
- References
- 64
- FWCI
- 35.03
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.